

# Financial Tear Sheet

## Corporate Profile

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, including glaucoma. In July 2017, the Company announced top-line results of its Phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial did not meet its primary efficacy endpoint and the Company has since discontinued development of trabodenoson in order to focus on evaluating strategic alternatives.

## Primary IR Contact

US Corporate Headquarters:  
Phone: 781-676-2100  
E-mail: [info@inotekpharma.com](mailto:info@inotekpharma.com)

## Stock Performance

### ITEK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$0.98
Change (%)	▼ 0.01 (0.00%)
Volume	15,636
52 Week High	\$9.69
52 Week Low	\$0.85
Market Cap	\$26,548,328
Rolling EPS	-1.53
PE Ratio	0
Shares Outstanding	27,010,202

Data as of 08/17/17 12:32 p.m. ET



## Recent News & Events

Aug 3, 2017

[Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights](#)

---

Jul 7, 2017

[Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update](#)

---

May 10, 2017

[Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights](#)

---

## SEC Filings

Filing Date	Form
08/08/17	8-K
08/03/17	SC 13D/A
08/03/17	10-Q
08/03/17	8-K

There are currently no events scheduled.

## Corporate Governance

<a href="#">David P. Southwell</a>	President and Chief Executive Officer
<a href="#">Rudolf A. Baumgartner, MD</a>	Executive Vice President, Chief Medical Officer
<a href="#">Dale Ritter</a>	Vice President, Finance & Chief Accounting Officer
<a href="#">Claudine Prowse, PhD</a>	Vice President, Strategy, Corporate Development & IRO
<a href="#">Cadmus C. Rich, MD, MBA, CPE</a>	Vice President, Clinical Development & Medical Affairs

Data provided by Nasdaq. Minimum 15 minutes delayed.